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Hodgkin lymphoma (HL) represents one of the most common non-AIDS-deﬁning cancers with an increasing incidence overtime.
Clinically, patients present advanced stages of disease with extranodal involvement in the majority of cases. In the last years,
signiﬁcant improvements in the treatment of patients with HL and HIV infection have been achieved. In the lack of randomized
trials, several phase II studies have showed that in the era of highly active antiretroviral therapy (HAART) the same regimens
employedinHIV-negativepatientswithHLcanbeusedinHIVsettingwithsimilarresults.Moreover,inthelastyearsthefeasibility
of high dose chemotherapy and peripheral stem cell rescue has allowed to save those patients who failed the upfront treatment.
Finally, in the near future, a better integration of diagnostic tools (including PET scan), chemotherapy (including new drugs),
radiotherapy, HAART, and supportive care will signiﬁcantly improve the outcome of these patients.
1.Introduction
The availability of highly active antiretroviral therapy
(HAART) has led to improvements in immune status among
HIV-infected persons, reducing AIDS-related morbidity and
prolonging survival. However, despite the impact of HAART
onHIV-relatedmortality,malignanciesremainanimportant
cause of death in the current era [1, 2]. The use of HAART
was also associated with reduced incidence of the two major
AIDS-associated malignancies—Kaposi’s sarcoma (KS) and
high-grade non-Hodgkin lymphoma (NHL) [3]. However,
among non-AIDS-deﬁning cancers, an increased risk of
Hodgkin lymphoma (HL), anal cancer, lung cancer, and
hepatocarcinoma has been recently observed [4].
Although HL is included in the World Health Organiza-
tion’scategorisationofHIV-associatedlymphomas[5,6],the
relation between HIV infection, AIDS, and HL is unclear.
HIV-associated HL (HIV-HL) displays several peculiar-
ities when compared with HL of the general population.
First, HIV-HL exhibits an unusually aggressive clinical
behavior, which mandates the use of speciﬁc therapeutic
strategies and is associated with a poor prognosis. Second,
the pathologic spectrum of HIV-HL diﬀers markedly from
that of HL in the general population [7, 8]. In particular,
the aggressive histological subtypes of classic HL (cHL),
namely, mixed cellularity (MC) and lymphocyte depletion
(LD), predominate among HIV-HL and the tumor tissue are
characterized by an unusually large proportion of neoplastic
cells, termed Reed-Sternberg (RS) cells [7]. Finally, despite
thegreatimprovementinchemotherapyandsupportivecare,
optimal staging and treatment is still a matter of controversy.
2. Epidemiology
In HIV-negative population of the western countries, HL
is one of the commonest malignancies diagnosed in young
adults with 6 cases per 100.000 inhabitants under 45
y e a r so fa g eo c c u re a c hy e a r[ 9], even if an increase in
incidence rate in the last decade has been observed [10].
The epidemiology of HL is characterized by a peculiar age
distribution pattern—a bimodal incidence curve with a ﬁrst
peak around the age of 30 and the second peak around the2 Advances in Hematology
age of 50 years—that has been taken as suggestive of an
infectious etiology.
In immune suppressed patients, HL occurs more fre-
quently than in the general population of the same age
and gender. Given the relative high frequency of HL in
the population groups at high risk for HIV infection,
epidemiological studies conducted during the ﬁrst years
of the HIV epidemic in North America and in Europe
had diﬃculties in including HL in the spectrum of HIV-
associated cancers. However, with the spread of the epidemic
and longer survival of infected people, the impact of HL
could be better recognized. All studies [4, 11–22]s t r o n g l y
supporttheevidencethatHIV-infectedpersonshave,overall,
a 10-fold higher risk of developing HL than HIV-negative
persons. HL in HIV-infected individuals is more frequent
in patients with moderate immune suppression and this is
in sharp contrast with KS and diﬀuse large B-cell NHL that
typically arise in a more pronounced immunosuppression
setting [4]. Thus, the epidemiological pattern of HL in
HAART era substantially diﬀers from those observed for
KS or NHL—two neoplasms which drastically decreased
after the introduction of HAART—and pose several new
questions with regard of the relationship between degree
of immunodeﬁciency, persistent viral infections and cancer.
Of some interest is the recent observation of Powles et
al. who have investigated the occurrence of cancers in a
prospective cohort of 11,112 HIV-positive individuals, with
71,687 patient-years of followup [23].
Standardized incidence ratios (SIRs) were calculated
using general population incidence data. The incidence of
HL in the HIV cohort was higher than in the general
population (SIR 13.85; 95% CI, 9.64 to 19.26). There was
a signiﬁcant increase in the SIRs across the three study
periods (1983 to 1995: 4.5; 1996 to 2001: 11.1, and 2002 to
2007: 32.4). Multivariate analysis demonstrated that HAART
was associated with an increased risk of disease (SIR 2.67;
95% CI, 1.19 to 6.02). Further multivariate modeling by
class of antiretroviral agents showed that of the three classes
of antiretroviral therapy, only the Non-Nucleoside Reverse
Transcriptase Inhibitors were associated with a signiﬁcant
increase in the incidence of HIV-HL (HR 2.20; 95% CI,
1.03 to 4.69). As the overall eﬀect of HAART is to increase
the CD4 count level, it paradoxically could increase HL
incidence. A potential mechanism emphasizes the role of the
RS cells producing several growth factors that increased the
inﬂux of CD4 cell and inﬂammatory cells, which, in turn,
provide proliferation signals for the RS neoplastic cells. One
can imagine that in the case of severe immune suppression,
leading to an unfavorable milieu, the progression of the RS
neoplastic cells can be compromised [24–26]. In addition,
HIV-HL is EBV−associated in almost all cases, in contrast
to what was observed in the general population, in which
this association is only observed in 20% to 50% according
to histological type and age at diagnosis [27]. Usurpation
of physiologically relevant pathways by EBV-encoded latent
membrane protein 1 (LMP1) may lead to the simultaneous
or sequential activation of signaling pathways involved in
the promotion of cell activation, growth, and survival,
contributing thus to most of the features of HIV-HL.
Whether this change aﬀects its categorization as HL or
whether it delays HL development is unknown.
In summary, the use of HAART has improved the
immunity of HIV-infected persons, diminishing the risks of
developing other cancers or other opportunistic infections
and paradoxically increasing the risk of HL.
3.Pathological Features
InthepreHAARTera,HIV-HLdisplayeddiﬀerentpatholog-
ical featuresin comparison with those of HL in HIV-negative
patients [7]. In fact, HIV-HL was characterized by the high
incidence of unfavorable histological subtypes (i.e., MC and
LD) [7, 8]. Among HIV-infected persons, MC was the most
frequent HL subtype whereas nodular sclerosis (NS) was
less frequent than in HIV-uninfected persons. For each HL
subtype, incidence decreasedwith declining CD4 counts,but
NS subtype decreased more precipitously than MC subtype,
thereby increasing the proportion of MC subtype of HL seen
in persons with HIV/AIDS. Thus, the greater proportion
o fM Ca n dL Ds u b t y p e sa p p e a r e ds p e c i ﬁ c a l l yr e l a t e dt o
severe immune compromise in HIV, while in HAART era
HIV-infected patients with modest immune compromise
are more at risk for the development of the NS subtype
[4]. CHL is a monoclonal lymphoid neoplasm, derived
from B cells, composed of mononuclear Hodgkin cells and
multinucleated Reed Stenberg (HRS) cells residing in a
cellular microenvironment. HRS cells consistently express
CD30 and CD40 and express CD15 in the majority of cases.
CD20 is positive in a minority of neoplastic cells in 30−40%
of cases, while the plasma cell-speciﬁc transcription factor
Interferon Regulatory Factor 4 (IRF4) is consistently positive
in HRS cells [5, 8].
On the other hand, HIV-HL may exhibit special features
related to the cellular background (presence of ﬁbrohistio-
cytoid stromal cell proliferation) and the high number of
the neoplastic cell. Both these features may pose relevant
diﬃculties in diagnosing and classifying the disease precisely.
In these cases, a large cell lymphoma of the anaplastic cell
type must be excluded on immunohistologic ground [7, 28].
A high frequency of EBV association has been shown
in HL (80−100%) tissues from HIV-HL [29, 30]. The EBV
genomesinsuchcaseshavebeenreportedtobeepisomaland
clonal, even when detected in multiple independent lesions.
The elevated frequency of EBV association with HIV-HL
indicates that EBV probably does represent a relevant factor
involved in the pathogenesis of HIV-HL. An etiologic role of
EBV in the pathogenesis of HIV-HL is further supported by
datashowingthatLMP-1isexpressedinvirtuallyallHIV-HL
cases [5, 28–31]. On these bases, HL in HIV-infected persons
appears to be an EBV-related lymphoma expressing LMP1.
Finally, RS cells of classical HL-of HIV-negative patients
represent transformed B-cells that originate from preapop-
toticgerminalcenter(GC)B-cells[32].MostHIV-relatedHL
cases express LMP1 and display the BCL6-/CD138+/MUM1
IRF4+ (for Multiple Myeloma-1 Interferon Regulatory
Factor-4), phenotype, thus reﬂecting post-GC B cells [29,
32]. The possible contribution of LMP1 to the loss of
BCL6 expression seems plausible given that LMP1 canAdvances in Hematology 3
downregulate many B-cell speciﬁc genes [33]. Loss of B-cell
identity occurs during the normal diﬀerentiation of a GC B-
cell into plasma cell or memory B-cell.
4. ClinicalAspects andTreatment
Similar to that observed in HIV-NHL, one of the most
peculiar features of HIV-HL is the widespread extent of the
disease at presentation and the frequency of systemic “B”
symptoms, including fever, night sweats, and/or weight loss
>10% of the normal body weight. At the time of diagnosis,
70−96% of the patients have “B” symptoms and 74−92%
have advanced stages of disease with frequent involvement
of extranodal sites, with the most common being bone
marrow (40−50%), and liver (15−40%) and spleen (around
20%) [8, 34–36]. HIV-HL tends to develop as an earlier
manifestation of HIV infection with higher median CD4+
cell count. [8, 34–36]. The widespread use of HAART
has resulted in substantial improvement in the survival of
patients with HIV infection and lymphomas, due to the
reduction of the incidence of opportunistic infections, the
opportunity to allow more aggressive chemotherapy, and
the less aggressive presentation of lymphoma in patients in
HAART in comparison with those lymphomas diagnosed in
patients who never received HAART [8, 34–37].
Within the Italian Cooperative Group on AIDS and
Tumors (GICAT), we have collected data on 290 patients
with HIV-HL. Two hundred and eighty-one patients (87%)
were males and the median age was 34 years (range 19−72
years) and 69% of patients were intravenous drug users. The
median CD4 cell count was 240/µL( r a n g e4 −1100/µL) and
57% of patients had a detectable HIV viral load.
MC was diagnosed in 53% of cases, followed by NS
in 24% and LD in 14%. Advanced stages of disease were
observed in 79% of patients and 76% had B symptoms. The
overall extranodal involvement was 59% with bone marrow,
spleen and liver involved in 38, 30, and 17, respectively.
With the aim to evaluate the impact of HAART on clinical
presentation and outcome of our patients, we split the
series into two subgroups: in the ﬁrst group we included
those patients who received HAART since 6 months before
the onset of HL (84 patients); in the second group we
included those patients who never received HAART before
the diagnosis of HL or less than 6 months (206 patients).
Brieﬂy,incomparisontoneverexperiencedHAART,patients
in HAART before the onset of HL are older, have less
B symptoms, a higher leukocyte, neutrophils count, and
hemoglobin level. The following parameters were associated
with a better overall survival (OS): MC subtype, the absence
of extranodal involvement, the absence of B symptoms,
and a prior use of HAART. Interestingly, three parameters
were associated with a better time to treatment failure: a
normal value of alkaline phosphatase, a prior exposure to
HAART, and an international prognostic score less than 3
[38]. A similar study was carried out within the Spanish
group GESIDA where the authors compared the clinical
characteristics and outcome of 104 patients with HIV-HL,
treated (83 patients) or not (21 patients) with HAART. No
diﬀerences were found between the groups at baseline, but
the complete remission (CR) rate was signiﬁcantly higher
in HAART group (91% versus 70%, P = .023). The median
overall survival was not reached in HAART group and was
39 months in no-HAART group (P = .0089); the median
disease-freesurvival(DFS)wasnotreachedinHAARTgroup
and was 85 months in no-HAART group (P = .129). Factors
independently associated with CR were a CD4 cell count
>100cells/µL and the use of HAART; CR was the only factor
independently associated with OS [39].
The optimal therapy for HIV-HL has not been deﬁned
yet. Because most patients have advanced stages of disease,
they have been treated with combination chemotherapy
regimens but the CR rate remains lower than that of HL
of the general population with the OS being approximately
1.5 years [8, 34–36]. Due to the low incidence of the disease,
no randomized controlled trials have been conducted in this
setting. However, several phase II studies have evaluated the
feasibility and activity of diﬀerent regimens. In a prospective
trial, conducted within the GICAT between March 1989 and
March 1992, 17 previously untreated patients with HIV-
HL were treated with epirubicin, vinblastine, and bleomycin
(EVB). Overall, CR was achieved in 53% of the total group,
lasting a median of 20 months. The median OS for the group
as a whole was 11 months and the 2-year DFS was 55%
[40]. In an attempt to improve upon these results, from
1993 to 1997, a second prospective trial consisting of full
dose EVB plus prednisone (EVBP regimen) and concomi-
tant antiretroviral therapy (zidovudine or didanosine) was
conducted. The results of this trial in which 35 patients were
enrolled, showed a CR rate of 74% and a 3-year OS and
DFS of 32% and 53%, respectively [41]. The AIDS Clinical
Trials Group (ACTG) reported the results of a phase II study
in 21 patients treated with ABVD chemotherapy for 4−6
cycles and primary use of G-CSF. Antiretroviral therapy was
not used. The CR rate, on an intent to treat analysis, was
43% with an overall objective response rate of 62%. Median
survival for all patients was 18 months [42]. Similar data
have been reported in a small trial with only 8 patients
enrolled [43]. The widespread use of HAART allows the use
of more aggressive chemotherapeutic regimens. We used the
Stanford V regimen, consisting of short-term chemotherapy
(12 weeks) with adjuvant radiotherapy. From May 1997 to
October 2001, 59 consecutive patients were treated in the
framework of this prospective phase II study within the
European Intergroup Study HL-HIV. Stanford V was well
tolerated and 69% of the patients completed treatment with
no dose reduction or delayed chemotherapy administration.
The most important dose-limiting side eﬀects were bone
marrow toxicity and neurotoxicity. Eighty-one percent of
the patients achieved CR and after a median followup of 17
months 33/59 (56%), patients are alive and disease-free. The
estimated 5-year OS, DFS, and freedom from progression
(FFP) were 59%, 68%, and 60%, respectively. Probability
of FFP was signiﬁcantly higher (P = .002) among patients
with an international prognostic score (IPS) of <2 than in
those with IPS >2, and the percentages of FFP at two years
were 83% and 41%, respectively. Similarly, probability of OS
was signiﬁcantly diﬀerent (P = .0004), and the percentage
of survival at three years was 76% and 33%, respectively for4 Advances in Hematology
Table 1: Results of prospective studies in HIV-HL.
Regimen/Reference No. of patients Stages III-IV Response rate Complete remission rate Overall survival
EBV [40] 17 88% 82% 53% 11 months
EBVP [41] 35 83% 91% 74% 16 months
ABVD [42] 21 81% 62% 43% 18 months
ABVD [43[ 8 75% 100% 100% 43.5 months
Stanford V [44] 59 71% 89% 81% 59% at 5 years
BEACOPP [45] 12 92% 100% 100% 75% at 3 years
ABVD [46] 62 100% 87% 87% 76% at 5 years
VEBEP [48] 71 70% 78% 67% 69% at 2 years
IPS <2a n dI P S>2[ 44]. Within the German group, the very
intensive BEACOPP regimen has been tested in 12 untreated
patients with a 100% of CR rate but a high incidence of
opportunistic infections [45]. Recently, the results of a large
prospective phase II study with ABVD have been published.
Within a cooperative network in Spain, 62 patients with
HIV-HL received the standard ABVD plus HAART. The
scheduled six to eight ABVD cycles were completed in
82% of cases. Six patients died during induction, 54 (87%)
achieved a CR, and two were resistant. The 5-year OS and
event-free survival (EFS) probabilities were 76% and 71%,
respectively. The immunological response to HAART had
ap o s i t i v ei m p a c to nO S( P = .002) and EFS (P = .001)
[46]. Interestingly, there are some anecdotic cases of use of
HAART with antineoplastic intent in HIV-NHL, especially
in primary eﬀusion lymphoma. Recently a case of long-
lasting response to HAART as the only therapy for HIV-
HL has been reported suggesting the possibility to use this
approach in selected cases [47]. Finally, within the GICAT
we have recently concluded the accrual of 71 patients in a
prospective phase II study aiming to evaluate feasibility and
activity of a novel regimen including epirubicin, bleomycin,
vinorelbine, cyclophosphamide, and prednisone (VEBEP
regimen). Seventy percent of patients had advanced stages
of disease and 45% had an IPS > 2. The CR was 67% and
2-year OS, DFS, TTF, and EFS were 69%, 86%, 59%, and
52%, respectively [48]. The results of the largest prospective
studies are showed in Table 1.
Because HIV-HL like other HL may progress or relapse,
the use of high dose chemotherapy and autologous stem
cell transplantation (ASCT) has been tested in this setting.
Several data from diﬀerent groups, including the GICAT,
havedemonstratedthefeasibilityofthisapproachthatcanbe
considered the gold standard in the salvage setting [49–53].
Diﬀerent conditioning regimens, including or not total body
irradiation, have been tested. Recently, the AIDS Malignancy
Consortium demonstrated in a multinstitutional trial that
a regimen of a dose-reduced high-dose chemotherapy,
including cyclophosphamide and busulfan and ASCT, is
well tolerated and is associated with favorable DFS and OS
probabilities for selected patients with HIV-associated NHL
and HL [54].
5.PETScanning
Positron Emission Tomography using [18F]-Fluoro-2-
Deoxy-D-Glucose (FDG-PET) was ﬁrst introduced in the
management of lymphomas in the early 1990s. It is now
recognised as an important tool for staging and treatment
response assessment in Hodgkin and non-Hodgkin lym-
phomas[55,56].Turningtopredictingoutcome,intheHIV-
negative patients, residual FDG PET avidity after 2 cycles
of ABVD has been shown to confer poor prognosis and
therefore,hasbeenproposedtoguidefuturetherapy[57,58].
A negative PET scan after two cycles of ABVD predicted a
96% 2-year progression-free survival (PFS). Nearly 80% of
the HL patients show a complete normalization of PET scan
a f t e rt w oc o u r s e so fA B V D[ 56]. This phenomenon, called
“metabolicCR”,canbeexplainedbythepeculiararchitecture
and organization of the neoplastic tissue, where only few,
scattered neoplastic cells (accounting for less than 1% of the
total cellular population) are surrounded by a population
of nonneoplastic mononuclear bystander cells. The latter
cells are probably responsible for the immortalisation of
Hodgkin and RS cells by stimulating cytokine production by
other CD4+ lymphoid cells (paracrine loop) or by inducing
cytokine production by the RS cells (autocrine loop). In
cases presenting with bulky lesions at diagnosis, a negative
early PET is often associated with a persisting bulky lesion of
more or less unchanged size. The explanation might be that
chemotherapy switches oﬀ the production of chemokines
by the activated lymphoid cells, as described for TARC
(Thymus and activation-related chemokine). The latter can
be measured in the serum of HL patients and its level is
correlated to the quality of treatment response: for patients
in CR the levels are much lower than in patients with stable
or progressing disease [59]. In contrast, PET scanning within
the HIV framework can be problematic. Some preliminary
reports suggested that FDG activity may correlate with
detectable lymphoma [60, 61]. Although initial staging may
not alter the treatment plan, it can provide additional
information, assess possible involvement of critical location,
and help foresee and possibly avoid further complications.
However, the experience with PET scanning in the HIV-
HL needs to be further studied. A baseline study is stronglyAdvances in Hematology 5
recommended, since early PET interpretation is based on a
site-to-site comparison of FDG uptake both before and after
chemotherapy. Pitfalls are numerous and bring a particular
challenge in these patients whom HIV-associated immun-
odeﬁciency predisposes to infection, as does the use of
aggressiveimmunosuppressivechemotherapyregimens[62].
PET imaging requires cautious reading and pertinent clinical
correlation to avoid diagnosing benign disease as malignant,
such as, hypermetabolic foci seen in lung or oesophagus,
which are common sites of HIV- and/or chemotherapy-
promoted infections. Nodal FDG uptake can be observed in
lymphoma, various infections (e.g., Mycobacterium avium
intracellular, Mycobacterium tuberculosis, Herpes simplex
virus, among others), and AIDS-related malignancies such
as Kaposi sarcoma. In addition, stimulation of bone marrow
following treatment with granulocyte colony stimulating
factors induces a striking increase in FDG uptake in bone
marrow. To take into account the possibility of minimal
residual uptake, a semiquantitative approach has recently
been proposed for interim PET interpretation in the context
of an international protocol for advanced-stage HL [63, 64].
Finally, PET is useful for an accurate initial staging and
it should be recommend to monitor treatment response,
because PET appears to have a prognostic value, since a
negative scan seems always associated with a favourable
outcome. Signiﬁcance of residual uptake at sites of disease
needs further evaluation (e.g., biopsy). However, the use of
FDG in the followup of HIV-HL patients who achieved CR
cannot be routinely recommended and further studies are
warranted prior to any deﬁnite conclusion.
6. Conclusions
The outcome of patients with HIV-HL has improved
with better combined antineoplastic and antiretroviral
approaches. The main important challenges for the next
yearsare(a)todemonstrateinarandomizedtrialthatABVD
is the standard regimen in HIV setting, (b) to validate the
role of PET scan both in the staging and in the evaluation of
response, (c) to better understand the interactions between
chemotherapy and antiretroviral therapy, in order to reduce
thetoxicityofbothapproaches,(d)toevaluatetheuseofnew
drugs(i.e.,bortezomib)inthissetting,and(e)toevaluatethe
long-term toxicity of the treatment in cured patients.
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